Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

New Jersey hospitals expand prostate cancer treatment with robotics, proton therapy and precision medicine innovations.

A new study may have found a potentially easier, less disruptive and more effective way to treat the second leading cause of ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy ...

Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63,000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward ...